Treatment-emergent peripheral neuropathy associated with bortezomib-based frontline regimens for multiple myeloma

Multiple Myeloma (MM)

Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting

Adv Ther

Fonseca R, Diels J, Ghilotti F, Mendes J, Van Hoorenbeeck S, Lee S, Schecter JM, Lendvai N, Patel N, Triguero A, Alsdorf W, van de Donk NWCJ, Ursi M

doi: 10.1007/s12325-025-03278-5

Multiple Myeloma (MM)

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Blood Cancer J

Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A

doi: 10.1038/s41408-025-01413-7

Multiple Myeloma (MM)

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

Blood Cancer J

Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A

doi: 10.1038/s41408-025-01253-5

Multiple Myeloma (MM)

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial

Lancet Haematol

Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV, DREAMM-7 trial study group

doi: 10.1016/S2352-3026(25)00163-2

Multiple Myeloma (MM)

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

J Clin Oncol

Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, Orfao A, Moreau P, Sonneveld P, Kumar SK, Dixon JG, Patel R, Bartlett BJ, Schecter J, McCarthy P, Hose D, Seckinger A, Mattia D, Goldschmidt H, Oliva S, Owen RG, Anderson KC, San-Miguel J, Durie BGM, Munshi N, International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group

doi: 10.1200/JCO-24-02020

Multiple Myeloma (MM)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Blood Cancer J

Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM, Chhabra S, Parrondo R, Ailawadhi S, Fotiou D, Dimopoulos MA, Yong K, Mactier C, Lau C, Corona M, Marin AJS, Mian H, Durie BG, Usmani SZ, Martin TG, Lin Y

doi: 10.1038/s41408-025-01259-z

Multiple Myeloma (MM)

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

Blood Cancer J

Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD Jr, Lee HC

doi: 10.1038/s41408-025-01414-6

Multiple Myeloma (MM)

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

Lancet Oncol

Mateos MV, San-Miguel J, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Yoon SS, Iosava G, Fujisaki T, Garg M, Ngo M, Katz EG, Krevvata M, Bolyard K, Carson R, Borgsten F, Dimopoulos MA

doi: 10.1016/S1470-2045(25)00018-X

Multiple Myeloma (MM)

Related content

Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM